Hunan Enterprise Develops “Minute-level” COVID-19 Nucleic Acid Testing System
Working staff operate the “minute-level” rapid nucleic acid testing system. (Photo provided by Sansure Biotech)
The Sansure Biotech Inc. announced on July 30 its independently-developed “minute-level” rapid nucleic acid testing system which does not require a professional laboratory environment for operation.
Sansure Biotech researchers pose with medical personnel. (Photo provided by Sansure Biotech)
With this new system, the detection results can come out in only 15 to 45 minutes.
Sansure Biotech working staff introduce COVID-19 nucleic acid testing device operation to clients in the Philippines. (Photo provided by Sansure Biotech)
This rapid testing system passed the authentication of the National Medical Products Administration and obtained CE certification (EU standard) in this April. It is a significant breakthrough which will not limit the application scenarios, such as a professional laboratory. It collects samples and gives out detection results. It is applicable for testing other diseases.
Sansure Biotech is a national gene detection technology application demonstration center, and also a state-local joint engineering research institute for infectious disease and oncogene diagnosis. Since the COVID-19 epidemic outbreak, it has given top priority to epidemic prevention and control, and made remarkable contributions to worldwide anti-epidemic fight.
Sansure Biotech working staff introduce installation and operation of the rapid nucleic acid testing system in Gabon. (Photo provided by Sansure Biotech)
mPharma, Sansure’s partner and the largest drug supply chain in Ghana, has provided six African countries with more than 100 sets of Sansure’s rapid nucleic acid testing analyzers. Chinese devices and diagnostic kits have served more than 10,000 users. “Sansure’s device has filled the gap of African countries in such field. It plays an important role in building a basic virus detection system in Africa”, mPharma CEO said.
Sansure’s COVID-19 nucleic acid diagnostic kits and analyzers have been used in more than 120 countries worldwide, especially in the fever clinics and emergency treatment testing laboratories.